PF-06444752

PF-06444752 is an investigational anti-IgE vaccine candidate developed by Pfizer for the treatment of allergic diseases such as allergic rhinitis and asthma. It is designed as a virus-like particle (VLP)-based vaccine to induce the production of anti-IgE antibodies, with the goal of reducing free IgE and IgE binding to effector cells, thereby attenuating allergic responses. This approach aims to provide an alternative to monoclonal antibody therapies by potentially offering a longer duration of action and lower cost. PF-06444752 has completed Phase 1 trials for allergic rhinitis and was under investigation for asthma and possibly for cough as part of broader anti-IgE strategies[1][3][5].